The current stock price of EAR is 2.57 USD. In the past month the price decreased by -2.65%. In the past year, price decreased by -66.14%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.98 | 216.73B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.52 | 203.04B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.45 | 141.90B | ||
| SYK | STRYKER CORP | 27.44 | 138.20B | ||
| IDXX | IDEXX LABORATORIES INC | 57.48 | 57.87B | ||
| BDX | BECTON DICKINSON AND CO | 14.06 | 57.87B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.3 | 48.17B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.93 | 39.58B | ||
| RMD | RESMED INC | 26.04 | 37.64B | ||
| DXCM | DEXCOM INC | 38.16 | 27.68B | ||
| PODD | INSULET CORP | 60.95 | 19.60B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.3 | 18.12B |
Eargo, Inc. is engaged in the development of hearing aids and headsets solutions. The company is headquartered in San Jose, California and currently employs 243 full-time employees. The company went IPO on 2020-10-16. The firm is engaged in developing products to improve the quality of life of people with hearing loss. Its Eargo hearing aids are virtually invisible, rechargeable, completely in-the-canal devices indicated to compensate for mild to moderate hearing loss. Its in-the-canal devices feature quality audio, which are designed to provide up to 16 hours of battery life and feature its soft flexible medical-grade silicon tips. The company is marketing various versions of hearing aids, the Eargo Max, the Eargo Neo HiFi, Eargo 5, Eargo 6 and Eargo 7. The firm markets and sells its hearing aids primarily in a direct-to-consumer format, engaging consumers through a mix of digital and traditional marketing as well as select commercial partnership, and omni-channel (including retail). Its devices are self-fitting hearing aids and are adjusted by the user to meet the user’s hearing needs, without pre-programming or a hearing test from a hearing care professional.
EARGO INC
2665 North First Street, Suite 300
San Jose CALIFORNIA 95110 US
CEO: Christian Gormsen
Employees: 243
Phone: 16503517700
Eargo, Inc. is engaged in the development of hearing aids and headsets solutions. The company is headquartered in San Jose, California and currently employs 243 full-time employees. The company went IPO on 2020-10-16. The firm is engaged in developing products to improve the quality of life of people with hearing loss. Its Eargo hearing aids are virtually invisible, rechargeable, completely in-the-canal devices indicated to compensate for mild to moderate hearing loss. Its in-the-canal devices feature quality audio, which are designed to provide up to 16 hours of battery life and feature its soft flexible medical-grade silicon tips. The company is marketing various versions of hearing aids, the Eargo Max, the Eargo Neo HiFi, Eargo 5, Eargo 6 and Eargo 7. The firm markets and sells its hearing aids primarily in a direct-to-consumer format, engaging consumers through a mix of digital and traditional marketing as well as select commercial partnership, and omni-channel (including retail). Its devices are self-fitting hearing aids and are adjusted by the user to meet the user’s hearing needs, without pre-programming or a hearing test from a hearing care professional.
The current stock price of EAR is 2.57 USD. The price decreased by -4.1% in the last trading session.
EAR does not pay a dividend.
EAR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
EARGO INC (EAR) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
The Revenue of EARGO INC (EAR) is expected to grow by 19.87% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
EARGO INC (EAR) currently has 243 employees.
ChartMill assigns a technical rating of 1 / 10 to EAR. When comparing the yearly performance of all stocks, EAR is a bad performer in the overall market: 90.64% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to EAR. EAR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months EAR reported a non-GAAP Earnings per Share(EPS) of -57.98. The EPS increased by 90.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -154.97% | ||
| ROE | -239.84% | ||
| Debt/Equity | 0 |
8 analysts have analysed EAR and the average price target is 2.04 USD. This implies a price decrease of -20.62% is expected in the next year compared to the current price of 2.57.
For the next year, analysts expect an EPS growth of 93.38% and a revenue growth 19.87% for EAR